Revance to be acquired for $900M+ as Botox trade secrets lawsuit continues

Revance Therapeutics, the maker of Botox competitor Daxxify, will be acquired for more than $900 million.

Crown Laboratories will buy out …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Renibus brings Series B total to $72M, securing registrational development for lead heart surgery candidate

Cardiorenal biotech Renibus Therapeutics has completed a Series B extension that brings its total proceeds to $72 million, securing a runway through registrational development and

September 13, 2023

Biden appoints Vanderbilt oncologist to head National Cancer Institute

WASHINGTON — President Biden on Friday said he plans to appoint cancer researcher and doctor Kimryn Rathmell to lead the National Cancer Institute. Rathmell will

November 17, 2023

Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin – Psychedelic Alpha

Leading psychiatrists and researchers examine common assumptions about the term “psychedelic-assisted psychotherapy” and the role of psychotherapy when evaluating psilocybin treatment. Authors highlight the need

July 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.